Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Wang, Shu Fang ^a,b   Fouquet, Stéphane ^a,b   Chapon, Maxime ^a,b   Salmon, Hélène ^a,b   Regnier, Fabienne ^a,b   Labroquère, Karine ^a,b   Badoual, Cécile ^c,d   Damotte, Diane ^b,e,f,g   Validire, Pierre ^h   Maubec, Eve ⁱ   Delongchamps, Nicolas B ^j   Cazes, Aurélie ^d,k   Gibault, Laure ^j   Garcette, Marylène ^a,b   Dieu Nosjean, Marie Caroline ^b,e,f   Zerbib, Marc ^j   Avril, Marie Françoise ^a,b,j   Prévost Blondel, Armelle ^a,b   Randriamampita, Clotilde ^a,b   Trautmann, Alain ^a,b   Bercovici, Nadège ^a,b   more..

^a INSTITUT COCHIN   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e CENTRE DE RECHERCHE DES CORDELIERS   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g HÔTEL DIEU   (France)

^h INSTITUT MUTUALISTE MONTSOURIS   (France)

ⁱ BICHAT HOSPITAL   (France)

^j Institut Mutualiste Montsouris ^*  (France)

^k INSERM   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; GAMMA INTERFERON; MITOGEN ACTIVATED PROTEIN KINASE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; STIBOGLUCONATE SODIUM; ANTIMONY GLUCONATE; APOPTOSIS REGULATORY PROTEIN; LEUKOCYTE ANTIGEN; LIGAND; PDCD1 PROTEIN, HUMAN;

ARTICLE; BONE MARROW CELL; CLONAL ANERGY; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; BIOPSY; CELL COMMUNICATION; DRUG EFFECT; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASM; PATHOLOGY; T LYMPHOCYTE;

MUS;

ANTIGENS, CD; ANTIMONY SODIUM GLUCONATE; APOPTOSIS REGULATORY PROTEINS; BIOPSY; CALCIUM; CELL COMMUNICATION; CLONAL ANERGY; HUMANS; LIGANDS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MYELOID CELLS; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 79952333102     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017621     Document Type: Article

References (36)

1. Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH, (2006) Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med 203: 2223-2227.
2. Frey AB, Monu N, (2008) Signaling defects in anti-tumor T cells. Immunol Rev 222: 192-205.
3. Rabinowitz JD, Beeson C, Wülfing C, Tate K, Allen P, et al. (1996) Altered T cell receptor ligands trigger a subset of early T cell signals. Immunity 5: 125-135.
4. Zea AH, Curti BD, Longo DL, Alvord WG, Strobl SL, et al. (1995) Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1: 1327-1335.
5. Broderick L, Brooks SP, Takita H, Baer AN, Bernstein JM, et al. (2006) IL-12 reverses anergy to T cell receptor triggering in human lung tumor-associated memory T cells. Clin Immunol 118: 159-169.
6. Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, et al. (2005) Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 201: 1257-1268.
7. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, et al. (2001) Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61: 4766-4772.
8. Attig S, Hennenlotter J, Pawelec G, Klein G, Koch SD, et al. (2009) Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res 69: 8412-8419.
9. Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Lienard D, et al. (2004) Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 64: 2865-2873.
10. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, et al. (2009) Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114: 1537-1544.
11. Zhang Y, Huang S, Gong D, Qin Y, Shen Q, (2010) Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol 7: 389-395.
12. Broderick L, Bankert RB, (2006) Membrane-associated TGF-beta1 inhibits human memory T cell signaling in malignant and nonmalignant inflammatory microenvironments. J Immunol 177: 3082-3088.
13. Gollmer K, Asperti-Boursin F, Tanaka Y, Okkenhaug K, Vanhaesebroeck B, et al. (2009) CCL21 mediates CD4+ T-cell costimulation via a DOCK2/Rac-dependent pathway. Blood 114: 580-588.
14. Stefanova II, Dorfman JR, Germain RN, (2002) Self-recognition promotes the foreign antigen sensitivity of naive T lymphocytes. Nature 420: 429-434.
15. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL, (2004) SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 173: 945-954.
16. Binstadt BA, Brumbaugh KM, Dick CJ, Scharenberg AM, Williams BL, et al. (1996) Sequential involvement of Lck and SHP-1 with MHC-recognizing receptors on NK cells inhibits FcR-initiated tyrosine kinase activation. Immunity 5: 629-638.
17. Fourmentraux-Neves E, Jalil A, Da Rocha S, Pichon C, Chouaib S, et al. (2008) Two opposite signaling outputs are driven by the KIR2DL1 receptor in human CD4+ T cells. Blood 112: 2381-2389.
18. Dong H, Chen X, (2006) Immunoregulatory role of B7-H1 in chronicity of inflammatory responses. Cell Mol Immunol 3: 179-187.
19. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, et al. (2006) Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66: 3381-3385.
20. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, et al. (2010) Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 107: 7875-7880.
21. Saibil SD, Deenick EK, Ohashi PS, (2007) The sound of silence: modulating anergy in T lymphocytes. Curr Opin Immunol 19: 658-664.
22. Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, et al. (2007) Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 56: 1173-1182.
23. Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, et al. (2007) PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 13: 1757-1761.
24. Demotte N, Stroobant V, Courtoy PJ, Van Der Smissen P, Colau D, et al. (2008) Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity 28: 414-424.
25. Leask A, Abraham DJ, (2004) TGF-beta signaling and the fibrotic response. FASEB J 18: 816-827.
26. Pathak MK, Yi T, (2001) Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J Immunol 167: 3391-3397.
27. Macian F, Garcia-Cozar F, Im SH, Horton HF, Byrne MC, et al. (2002) Transcriptional mechanisms underlying lymphocyte tolerance. Cell 109: 719-731.
28. Chiodetti L, Choi S, Barber DL, Schwartz RH, (2006) Adaptive tolerance and clonal anergy are distinct biochemical states. J Immunol 176: 2279-2291.
29. Rivas MN, Weatherly K, Hazzan M, Vokaer B, Dremier S, et al. (2009) Reviving function in CD4+ T cells adapted to persistent systemic antigen. J Immunol 183: 4284-4291.
30. Good-Jacobson KL, Szumilas CG, Chen L, Sharpe AH, Tomayko MM, et al. (2010) PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat Immunol 11: 535-542.
31. Wong RM, Scotland RR, Lau RL, Wang C, Korman AJ, et al. (2007) Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol 19: 1223-1234.
32. Fourcade J, Kudela P, Sun Z, Shen H, Land SR, et al. (2009) PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol 182: 5240-5249.
33. Sundar S, Rai M, (2002) Advances in the treatment of leishmaniasis. Curr Opin Infect Dis 15: 593-598.
34. Derre L, Rivals JP, Jandus C, Pastor S, Rimoldi D, et al. (2010) BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest 120: 157-167.
35. Delon J, Bercovici N, Liblau R, Trautmann A, (1998) Imaging antigen recognition by naive CD4+ T cells: compulsory cytoskeletal alterations for the triggering of an intracellular calcium response. Eur J Immunol 28: 716-729.
36. Asperti-Boursin F, Real E, Bismuth G, Trautmann A, Donnadieu E, (2007) CCR7 ligands control basal T cell motility within lymph node slices in a phosphoinositide 3-kinase- independent manner. J Exp Med 204: 1167-1179.